Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Migraine therapeutics differentially modulate the CGRP pathway
Minoti Bhakta, Trang Vuong, Tetsuya Taura, et al.
Cephalalgia (2021) Vol. 41, Iss. 5, pp. 499-514
Open Access | Times Cited: 80

Showing 1-25 of 80 citing articles:

CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Andrew F. Russo, Debbie L. Hay
Physiological Reviews (2022) Vol. 103, Iss. 2, pp. 1565-1644
Open Access | Times Cited: 162
Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions
Linda Al‐Hassany, Peter J. Goadsby, A.H. Jan Danser, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 3, pp. 284-294
Closed Access | Times Cited: 99
Shared and independent roles of CGRP and PACAP in migraine pathophysiology
Adisa Kuburas, Andrew F. Russo
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 49
The role of TRP ion channels in migraine and headache
Luigi Francesco Iannone, Francesco De Logu, Pierangelo Geppetti, et al.
Neuroscience Letters (2021) Vol. 768, pp. 136380-136380
Closed Access | Times Cited: 56
Constipation Caused by Anti-calcitonin Gene-Related Peptide Migraine Therapeutics Explained by Antagonism of Calcitonin Gene-Related Peptide’s Motor-Stimulating and Prosecretory Function in the Intestine
Peter Holzer, Ulrike Holzer‐Petsche
Frontiers in Physiology (2022) Vol. 12
Open Access | Times Cited: 55
Blood Pressure in Patients With Migraine Treated With Monoclonal Anti-CGRP (Receptor) Antibodies
Simone de Vries Lentsch, Britt W. H. van der Arend, Antoinette MaassenVanDenBrink, et al.
Neurology (2022) Vol. 99, Iss. 17
Open Access | Times Cited: 50
Migraine monoclonal antibodies against CGRP change brain activity depending on ligand or receptor target – an fMRI study
Hauke Basedau, Lisa-Marie Sturm, Jan Mehnert, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 43
Salivary CGRP and Erenumab Treatment Response: Towards Precision Medicine in Migraine
Alicia Alpuente, Victor J Gallardo, Laila Asskour, et al.
Annals of Neurology (2022) Vol. 92, Iss. 5, pp. 846-859
Closed Access | Times Cited: 43
Mode and site of action of therapies targeting CGRP signaling
Alejandro Labastida‐Ramírez, Edoardo Caronna, Cédric Gollion, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 33
Future targets for migraine treatment beyond CGRP
Linda Al‐Hassany, Deirdre M. Boucherie, Hannah Creeney, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 29
Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study
Andreas Straube, Gregor Broessner, Charly Gaul, et al.
The Journal of Headache and Pain (2023) Vol. 24, Iss. 1
Open Access | Times Cited: 26
Switching anti-CGRP(R) monoclonal antibodies in multi-assessed non-responder patients and implications for ineffectiveness criteria: A retrospective cohort study
Luigi Francesco Iannone, Andrea Burgalassi, Giulia Vigani, et al.
Cephalalgia (2023) Vol. 43, Iss. 4
Open Access | Times Cited: 25
Roles of calcitonin gene-related peptide in the skin, and other physiological and pathophysiological functions
Yee Jung Kim, Richard D. Granstein
Brain Behavior & Immunity - Health (2021) Vol. 18, pp. 100361-100361
Open Access | Times Cited: 46
Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine—Clinical Considerations: A Narrative Review
Jessica Ailani, Eric A. Kaiser, Paul G. Mathew, et al.
Neurology (2022) Vol. 99, Iss. 19, pp. 841-853
Open Access | Times Cited: 37
Migraine: Advances in the Pathogenesis and Treatment
Horia Pleș, Ioan Alexandru Florian, Teodora-Larisa Timiș, et al.
Neurology International (2023) Vol. 15, Iss. 3, pp. 1052-1105
Open Access | Times Cited: 18
Potential treatment targets for migraine: emerging options and future prospects
Chia‐Chun Chiang, Frank Porreca, Carrie E. Robertson, et al.
The Lancet Neurology (2024) Vol. 23, Iss. 3, pp. 313-324
Closed Access | Times Cited: 8
Rizatriptan benzoate-loaded dissolving microneedle patch for management of acute migraine therapy
Chao Zhong, Xiufeng Zhang, Yanfang Sun, et al.
Journal of Biomaterials Applications (2024) Vol. 38, Iss. 9, pp. 989-999
Open Access | Times Cited: 7
Pharmacology of erenumab in human isolated coronary and meningeal arteries: Additional effect of gepants on top of a maximum effect of erenumab
Tessa de Vries, Eloísa Rubio‐Beltrán, Antoon van den Bogaerdt, et al.
British Journal of Pharmacology (2024) Vol. 181, Iss. 12, pp. 1720-1733
Open Access | Times Cited: 6
Novel insight into atogepant mechanisms of action in migraine prevention
Agustín Melo-Carrillo, Andrew M. Strassman, Ron S. Broide, et al.
Brain (2024) Vol. 147, Iss. 8, pp. 2884-2896
Open Access | Times Cited: 6
CGRP receptor antagonists for migraine. Are they also AMY1 receptor antagonists?
Michael L. Garelja, Christopher S. Walker, Debbie L. Hay
British Journal of Pharmacology (2021) Vol. 179, Iss. 3, pp. 454-459
Open Access | Times Cited: 34
A narrative review of the calcitonin peptide family and associated receptors as migraine targets: Calcitonin gene‐related peptide and beyond
Michael L. Garelja, Debbie L. Hay
Headache The Journal of Head and Face Pain (2022) Vol. 62, Iss. 9, pp. 1093-1104
Open Access | Times Cited: 23
An observational study on monoclonal antibodies against calcitonin‐gene‐related peptide and its receptor
Francesca Schiano di Cola, Marco Bolchini, Giulia Ceccardi, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 6, pp. 1764-1773
Open Access | Times Cited: 16
Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series
Katharina Kaltseis, Vera Filippi, Florian Frank, et al.
BMC Neurology (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 16
Migraine Treatment: Towards New Pharmacological Targets
Marcello Silvestro, Luigi Francesco Iannone, Ilaria Orologio, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 15, pp. 12268-12268
Open Access | Times Cited: 16
Depression and treatment with anti‐calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine
Simone de Vries Lentsch, Britt W. H. van der Arend, Irene de Boer, et al.
European Journal of Neurology (2023) Vol. 31, Iss. 2
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top